Ascendis Pharma A/S $ASND Shares Sold by Spyglass Capital Management LLC

Spyglass Capital Management LLC trimmed its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 11.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 367,972 shares of the biotechnology company’s stock after selling 47,577 shares during the period. Ascendis Pharma A/S comprises about 6.0% of Spyglass Capital Management LLC’s investment portfolio, making the stock its 2nd largest holding. Spyglass Capital Management LLC’s holdings in Ascendis Pharma A/S were worth $84,166,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of ASND. Rhumbline Advisers raised its position in shares of Ascendis Pharma A/S by 4.0% during the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 55 shares during the period. Certuity LLC grew its position in shares of Ascendis Pharma A/S by 5.7% in the 4th quarter. Certuity LLC now owns 1,170 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 63 shares during the period. Personal CFO Solutions LLC grew its position in shares of Ascendis Pharma A/S by 4.4% in the 1st quarter. Personal CFO Solutions LLC now owns 1,519 shares of the biotechnology company’s stock valued at $347,000 after purchasing an additional 64 shares during the period. EverSource Wealth Advisors LLC increased its stake in Ascendis Pharma A/S by 34.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 69 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its stake in Ascendis Pharma A/S by 15.1% during the 4th quarter. Farther Finance Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 72 shares in the last quarter.

Insider Activity

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime purchased 400 shares of Ascendis Pharma A/S stock in a transaction that occurred on Tuesday, May 26th. The stock was acquired at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the completion of the acquisition, the director owned 400 shares of the company’s stock, valued at approximately $95,120. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The disclosure for this sale is available in the SEC filing. Company insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Trading Up 0.4%

NASDAQ ASND opened at $254.44 on Wednesday. The company has a market cap of $15.87 billion, a PE ratio of 29.35 and a beta of 0.37. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. Ascendis Pharma A/S has a 12 month low of $160.86 and a 12 month high of $282.15. The stock has a 50 day moving average of $244.72 and a 200-day moving average of $234.20.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.11. The firm had revenue of $285.45 million during the quarter, compared to the consensus estimate of $362.47 million. On average, equities research analysts anticipate that Ascendis Pharma A/S will post 4.49 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on ASND. Oppenheimer reiterated an “outperform” rating on shares of Ascendis Pharma A/S in a report on Tuesday, June 9th. Royal Bank Of Canada boosted their price objective on shares of Ascendis Pharma A/S from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Citigroup initiated coverage on shares of Ascendis Pharma A/S in a research note on Monday, May 18th. They issued a “buy” rating and a $355.00 target price for the company. Morgan Stanley increased their target price on Ascendis Pharma A/S from $256.00 to $275.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Finally, Evercore reissued an “outperform” rating and issued a $329.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $296.72.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.